CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 742,670 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05768945
NCT05768945N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Brigham and Women's Hospital·observational·Posted Mar 15, 2023·Updated Nov 10, 2025

In Brief

An observational study evaluating Semaglutide and DPP-4 inhibitor for Diabetes. Completed, enrolled 742,670 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
2023202420252026
First PostedMar 15, 2023
Enrollment StartNov 30, 2022
Primary CompletionJul 7, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.3 years ago

Interventions

Semaglutidedrug

Semaglutide claim is used as the exposure group.

DPP-4 inhibitordrug

DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.